Sunovion To Commercialize Novartis’s COPD Products In US
Sunovion has secured US rights to Novartis's respiratory inhalers, and will cash in on Novartis's FLAME data in COPD patients which recently helped change treatment guidelines.
You may also be interested in...
Facing the looming loss of exclusivity for its top product, Sumitomo Dainippon Pharma is looking to its late-stage pipeline and recent product and corporate acquisitions to help plug the hole.
Busy stretch before Christmas holidays sees two deals around oncolytic virus therapeutics, a Middle East partnership for Orexigen’s Contrave, immuno-oncology deals involving Pfizer and ElsaLys, and Roche and ImmuNext partnering to develop drugs targeting the VISTA pathway.
There has been some criticism of the recent update to COPD management guidelines published by GOLD, with concern over the how much of the changes are based on clinical evidence.